GO:0043274 phospholipase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043274 phospholipase binding is a molecular function defined as binding to a phospholipase, the enzyme class that hydrolyzes phospholipids.
• Phospholipase binding controls enzyme recruitment, interfacial activation, and substrate access, and is central to receptor-driven lipid signaling.
• Key binding partners include GTP-binding proteins, annexins/lipocortins, sperm factors such as PLCZ1 and PAWP, and bacterial CBASS effectors.
• Dysregulated phospholipase binding contributes to inflammation, cardiovascular disease, cancer, and infertility.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of phospholipase-binding interfaces.
• EDITGENE provides end-to-end cell model and CRISPR library screening services for phospholipase binding research.
Description
GO:0043274 phospholipase binding is a molecular function term describing the selective, non-covalent interaction of a protein or other molecule with a phospholipase enzyme. Phospholipases are a large enzyme superfamily that hydrolyze phospholipids at specific ester bonds, generating second messengers such as arachidonic acid, diacylglycerol, and inositol trisphosphate. Because these enzymes act at membrane interfaces, their activity is frequently controlled by binding partners that recruit them to the correct membrane, stabilize an active conformation, or scaffold them into signaling complexes. The QuickGO definition of GO:0043274 is deliberately broad: it captures any binding event whose target is a phospholipase, regardless of the phospholipase class or the chemical nature of the binding partner. For researchers, phospholipase binding is a convergence point for signal transduction, innate immunity, and membrane remodeling. Receptor-mediated activation of phospholipase A2 and phospholipase C through distinct GTP-binding proteins established the paradigm that binding partners dictate which phospholipase is switched on downstream of a given receptor. More recent work has extended this principle to bacterial cyclic-dinucleotide-induced CBASS immunity, where phospholipase effectors assemble into filaments and disrupt membranes after ligand binding. In parallel, sperm-factor biology has debated whether PLCZ1 or PAWP is the physiological phospholipase-binding activator delivered by the sperm to trigger calcium oscillations in the egg. These examples show that phospholipase binding is not a passive interaction but a regulatory decision point. This article integrates the QuickGO definition of GO:0043274 with verified PubMed literature to summarize the mechanism, key genes, disease relevance, and experimental methods used to study phospholipase binding. It is written for molecular biologists, drug-discovery scientists, and computational biologists who need a citable, entity-level overview of this GO term.
phospholipase binding At A Glance
| GO ID | GO:0043274 |
|---|---|
| GO term | phospholipase binding |
| Ontology | molecular_function |
| Synonym | none listed in QuickGO |
| Definition | Binding to a phospholipase. |
| Major function | Recruitment, interfacial activation, and regulation of phospholipase enzymes at membranes |
| Representative binders | GTP-binding proteins, annexins/lipocortins, PLCZ1, PAWP, CBASS effector partners |
| Disease links | Inflammation, cardiovascular disease, cancer, infertility |
| Research methods | CRISPR KO/point mutation/knock-in, lipid binding assays, structural biology, imaging |
What Is GO:0043274?
In our own words, GO:0043274 phospholipase binding is the molecular function of selectively and non-covalently interacting with a phospholipase enzyme. The term does not specify which phospholipase family is bound, nor does it require that binding alters catalytic activity; it simply records that a physical binding event occurs between the annotated protein and a phospholipase. This makes GO:0043274 a useful parent-level annotation for receptor-G-protein-phospholipase coupling, annexin/lipocortin inhibition of phospholipase A2, sperm-factor delivery of PLCZ1 or PAWP, and bacterial effector assembly on membranes.
Why Is phospholipase binding Important in Cell Biology?
Phospholipase binding is important because it determines when, where, and how a phospholipase acts. Phospholipases are dangerous enzymes: uncontrolled hydrolysis of membrane phospholipids can destroy membrane integrity or produce excessive lipid second messengers. Binding partners solve this problem by acting as molecular switches, membrane tethers, or inhibitors. For example, distinct GTP-binding proteins activate phospholipase A2 and phospholipase C downstream of alpha 1-adrenergic stimulation, showing that binding specificity routes receptor signals to different lipid pathways. Annexins/lipocortins bind and inhibit phospholipase A2, providing a brake on arachidonic acid release. In bacteria, cyclic-dinucleotide-induced filamentous assembly of phospholipases governs broad CBASS immunity, and the CapV effector disrupts membranes through defined molecular mechanisms. Because phospholipase binding sits at the top of these pathways, it is a high-value target for mechanistic studies and therapeutic intervention.
• Controls receptor-mediated activation of phospholipase A2 and phospholipase C by distinct GTP-binding proteins.
• Regulates arachidonic acid and eicosanoid second-messenger production in inflammation.
• Determines interfacial activation kinetics of phospholipase A2 at lipid/water interfaces.
• Underpins sperm-factor biology, where PLCZ1 and PAWP are candidate phospholipase-binding activators of egg calcium oscillations.
• Mediates bacterial CBASS immunity through cyclic-dinucleotide-induced phospholipase filament assembly.
• Enables membrane disruption by the CBASS effector CapV, a model for phospholipase-driven antibacterial defense.
• Provides structural templates for lipid binding and catalysis, as shown for Mycobacterium tuberculosis Rv3802.
• Links lipid signaling to cardiovascular, inflammatory, and neoplastic disease processes.
• Offers druggable protein-protein interfaces for modulating phospholipase activity.
• Supports CRISPR-based causal genetics of phospholipase-binding interfaces in human cells.
Molecular Mechanism of phospholipase binding
Membrane recruitment and interfacial docking
In simple terms: Binding partners bring phospholipases to the membrane surface where their lipid substrates sit.
Phospholipases act on lipids organized at membrane interfaces, so productive catalysis requires the enzyme to dock onto a lipid/water interface. Binding partners such as GTP-binding proteins and membrane-associated scaffolds increase the local concentration of phospholipase at the correct membrane. Kinetic studies of phospholipase A2 binding to lipid/water interfaces show that interfacial activation depends on the physical state and packing of the membrane, not only on soluble enzyme concentration. This means phospholipase binding is partly a targeting function: the binder determines which membrane the enzyme samples and how long it remains there.
G-protein-coupled activation of phospholipase A2 and phospholipase C
In simple terms: Different G-proteins bind and switch on different phospholipases after a receptor is stimulated.
Receptor-mediated activation of phospholipase A2 via GTP-binding proteins generates arachidonic acid and its metabolites as second messengers. In FRTL5 thyroid cells, alpha 1-adrenergic stimulation activates phospholipase A2 and phospholipase C through distinct GTP-binding proteins, demonstrating that binding specificity separates the two lipid pathways. This dual control allows a single receptor to produce multiple lipid signals with different kinetics and downstream targets. The molecular basis is direct binding of activated G-protein subunits to the phospholipase, which relieves autoinhibition and promotes membrane engagement.
Inhibitory binding by annexins and lipocortins
In simple terms: Some proteins bind phospholipases to shut them down rather than turn them on.
Lipocortin is a calcium-binding protein with anti-phospholipase A2 activity, illustrating that phospholipase binding can be inhibitory. By sequestering phospholipase A2 or blocking its access to substrate, annexin/lipocortin family proteins limit arachidonic acid release and dampen inflammatory signaling. This inhibitory mode of phospholipase binding is conceptually important because it shows the term GO:0043274 covers both activating and repressing interactions.
Sperm-factor delivery of PLCZ1 and PAWP
In simple terms: The sperm delivers a phospholipase-binding activator that switches on calcium waves in the egg.
Phospholipase C zeta (PLCZ1) and postacrosomal sheath WW domain-binding protein (PAWP) have been proposed as sperm factors that trigger egg activation. The debate over which molecule survives as the physiological sperm factor centers on whether it binds and activates the egg phospholipase machinery in a way that reproduces calcium oscillations. This is a direct example of phospholipase binding as a developmental trigger, and it remains an active area of reproductive biology.
Cyclic-dinucleotide-induced phospholipase assembly in CBASS immunity
In simple terms: Bacteria assemble phospholipases into filaments when they detect a viral invasion signal.
Cyclic-dinucleotide-induced filamentous assembly of phospholipases governs broad CBASS immunity, converting a soluble effector into an oligomeric membrane-attacking machine. The CBASS phospholipase effector CapV disrupts membranes through defined molecular mechanisms, including lipid binding and conformational change. Structural and mechanistic studies of Mycobacterium tuberculosis Rv3802 provide a complementary view of lipid binding and catalysis in a phospholipase with a defined fold. Together, these systems show that phospholipase binding and assembly can be programmed by nucleotide second messengers and protein-protein interfaces.
Key Genes Involved in GO:0043274 phospholipase binding
The following genes and proteins are established or strongly implicated participants in phospholipase binding events, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G4A | Cytosolic phospholipase A2 that releases arachidonic acid | Model for GTP-binding-protein-coupled phospholipase binding |
| PLCB1 | Phospholipase C beta activated by G-proteins | Prototype for receptor-to-phospholipase binding specificity |
| PLCZ1 | Sperm phospholipase C zeta candidate egg-activating factor | Central to sperm-factor phospholipase binding debate |
| PAWP | Postacrosomal sheath WW domain-binding protein | Alternative sperm factor proposed to bind phospholipase machinery |
| ANXA1 | Annexin A1/lipocortin with anti-phospholipase A2 activity | Inhibitory phospholipase binding and inflammation control |
| ANXA2 | Annexin A2 calcium-dependent membrane-binding protein | Model for calcium-regulated phospholipase binding |
| GNAS | G-protein alpha subunit that couples receptors to effectors | Defines G-protein-phospholipase binding interfaces |
| GNAI1 | Inhibitory G-protein alpha subunit | Contrasts activating versus inhibitory phospholipase coupling |
| Rv3802 | Mycobacterial phospholipase with defined lipid binding | Structural template for lipid binding and catalysis |
| CapV | CBASS phospholipase effector that disrupts membranes | Model for nucleotide-induced phospholipase assembly |
| CBASS effector operons | Bacterial immunity modules encoding phospholipases | Broad phospholipase assembly and immunity studies |
| PLA2G2A | Secretory phospholipase A2 family member | Interfacial binding and activation studies |
| PLA2G1B | Pancreatic secretory phospholipase A2 | Kinetic model for lipid/water interface binding |
| PLA2G6 | Calcium-independent phospholipase A2 | Candidate for membrane remodeling and disease models |
| PLD1 | Phospholipase D isoform | Binding-dependent membrane recruitment studies |
| PLD2 | Phospholipase D isoform | Binding-dependent membrane recruitment studies |
| PIK3CA | Phosphoinositide 3-kinase catalytic subunit | Lipid kinase that interfaces with phospholipase signaling |
How Is phospholipase binding Regulated?
Phospholipase binding is regulated at multiple levels. Receptor occupancy controls the release of activated GTP-binding proteins that bind and switch on phospholipase A2 or phospholipase C. Calcium influx regulates annexin/lipocortin binding to phospholipases, providing a calcium-dependent brake on arachidonic acid release. Membrane lipid composition and interfacial packing regulate the docking and interfacial activation of phospholipase A2, so changes in membrane order can alter binding outcomes. In bacteria, cyclic dinucleotides trigger filamentous assembly of phospholipases, linking second-messenger availability to phospholipase binding and membrane attack. Finally, developmental timing controls sperm-factor delivery of PLCZ1 or PAWP to the egg, where phospholipase binding initiates calcium oscillations.
phospholipase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G4A | Inflammatory and eicosanoid signaling | Point-mutation knock-in of binding interface in myeloid cells |
| PLCB1 | G-protein-coupled lipid signaling | Knockout and rescue in HEK293 or neuronal lines |
| PLCZ1 | Fertilization failure and egg activation | Knock-in of patient variants in oocyte-like models |
| ANXA1 | Inflammation and glucocorticoid response | Knockout in macrophages with lipocortin rescue |
| CapV | Bacterial CBASS immunity and membrane attack | Bacterial knockout and filament assembly assays |
Inflammation and eicosanoid-driven disease
Phospholipase A2 binding by GTP-binding proteins releases arachidonic acid, the precursor of prostaglandins and leukotrienes, which are central mediators of inflammation. Inhibitory phospholipase binding by lipocortin/annexin proteins restrains this pathway, and loss of such inhibition can amplify inflammatory signaling. Therefore, proteins that bind phospholipases are candidate targets for anti-inflammatory strategies.
Cardiovascular and metabolic signaling
Receptor-mediated activation of phospholipase A2 and phospholipase C through distinct GTP-binding proteins shapes second-messenger balance in excitable and endocrine tissues. Because these pathways influence vascular tone, platelet function, and metabolic signaling, altered phospholipase binding can contribute to cardiovascular and metabolic phenotypes. Experimental models that mutate binding interfaces are needed to test causality.
Cancer and cell proliferation
Lipid second messengers produced downstream of phospholipase activation feed into proliferation and survival signaling. Binding partners that recruit phospholipases to specific membranes can therefore influence oncogenic signaling strength and duration. Targeting phospholipase-binding interfaces is an emerging strategy to modulate these pathways without abolishing enzyme expression.
Infertility and egg activation failure
The sperm-factor hypothesis proposes that PLCZ1 or PAWP delivered by the sperm binds and activates the egg phospholipase machinery to trigger calcium oscillations. Failure of this phospholipase-binding event is a candidate mechanism of fertilization failure and male infertility. Research in this area directly tests which sperm protein is the physiological phospholipase-binding activator.
From phospholipase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene bind phospholipase in cells? | Endogenous tagged knock-in with co-immunoprecipitation |
| Which residue mediates phospholipase binding? | Point-mutation knock-in of the predicted interface |
| Is phospholipase binding required for signaling? | Knockout plus wild-type or binding-dead rescue |
| Does overexpression drive lipid second messengers? | Doxycycline-inducible overexpression cell line |
| Which genes modify phospholipase binding phenotypes? | Genome-wide CRISPR knockout library screening |
| How does binding change membrane localization? | Tagged knock-in with live-cell imaging |
How to Study the phospholipase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction with phospholipase | Validate candidate binding partners |
| Lipid vesicle binding assay | Interfacial docking and activation | Measure phospholipase A2 binding kinetics |
| Crystal structure / cryo-EM | Binding interface and catalytic geometry | Define lipid binding pockets |
| Live-cell imaging | Membrane recruitment dynamics | Track receptor-driven phospholipase binding |
| Calcium imaging | Egg activation and signaling output | Test PLCZ1 versus PAWP sperm factor |
| CRISPR knockout | Loss-of-function phenotype | Test requirement for phospholipase binding |
| CRISPR point mutation | Residue-level causality | Separate binding from catalysis |
| CRISPR library screen | Genome-wide modifiers | Discover new phospholipase-binding regulators |
Binding and interaction assays
Co-immunoprecipitation, pull-down, and proximity labeling are used to detect phospholipase binding partners in lysates and intact cells. Lipid binding assays with defined vesicles measure interfacial docking and activation of phospholipases such as phospholipase A2. These methods establish whether a candidate protein physically associates with a phospholipase and under what lipid conditions.
Structural and biophysical analysis
Crystal structures and biochemical assays of phospholipases such as Mycobacterium tuberculosis Rv3802 reveal lipid binding pockets and catalytic residues that define how binding partners present substrate. Structural studies of CBASS phospholipase effectors show how nucleotide-induced assembly creates membrane-disrupting surfaces. These approaches generate hypotheses that can be tested by mutation.
Cell signaling and imaging
Live-cell imaging of tagged phospholipases and binding partners tracks recruitment to membranes after receptor stimulation. Calcium imaging and second-messenger reporters measure functional consequences of phospholipase binding in real time. These methods connect molecular binding events to physiological outputs such as calcium oscillations or arachidonic acid release.
Genetic and CRISPR perturbation
CRISPR knockout, point mutation, knock-in tagging, and overexpression allow causal testing of phospholipase-binding interfaces. Library screening can identify modifiers of phospholipase-dependent phenotypes, and bioinformatic analysis prioritizes candidate binders. Combining perturbation with the assays above provides a rigorous functional pipeline.
How CRISPR Can Be Used to Study GO:0043274 phospholipase binding
Knockout
CRISPR knockout of candidate phospholipase-binding genes removes the binder and reveals whether phospholipase-dependent signaling is lost. Knockout of bacterial CBASS phospholipase effectors abolishes immunity, providing a clean loss-of-function benchmark. In human cells, knockout of G-protein or annexin genes can test their requirement for phospholipase activation or inhibition.
Point Mutation
Point-mutation knock-in of predicted binding-interface residues separates phospholipase binding from other functions of the protein. This is essential when a gene has both catalytic and scaffolding roles, as seen for phospholipases with defined lipid binding pockets. Binding-dead mutants can be compared with wild-type in rescue experiments.
Knock-in
Tagged knock-in of endogenous phospholipases or their binding partners enables physiological interaction mapping without overexpression artifacts. Fluorescent or epitope tags support imaging and co-immunoprecipitation from native chromatin and membrane contexts. Knock-in of disease-associated variants tests whether patient mutations alter phospholipase binding.
Overexpression
Inducible overexpression of a phospholipase or its binder amplifies the pathway and makes biochemical detection easier. Overexpression can also reveal dominant-negative or gain-of-function effects of binding-interface mutants. Dose-controlled systems are preferred because excessive phospholipase activity can disrupt membranes non-specifically.
How EDITGENE Supports phospholipase binding Research
Researchers studying phospholipase binding-related genes often need to determine whether a candidate gene is causally involved in phospholipase recruitment, activation, or inhibition, and which residues mediate the interaction. Answering these questions requires clean genetic models in which binding can be removed, mutated, tagged, or amplified without confounding artifacts. EDITGENE provides these models together with screening and bioinformatics support tailored to GO:0043274 research.
Contact EDITGENE today to design your custom CRISPR model for phospholipase binding research.
Frequently Asked Questions About phospholipase binding
What is phospholipase binding (GO:0043274)?
GO:0043274 phospholipase binding is a molecular function defined as binding to a phospholipase, the enzyme class that hydrolyzes phospholipids.
What genes are involved in phospholipase binding?
Representative genes include PLA2G4A, PLCB1, PLCZ1, PAWP, ANXA1, ANXA2, GNAS, GNAI1, Rv3802, and CapV.
How is phospholipase binding regulated?
It is regulated by receptor-driven GTP-binding protein activation, calcium-dependent annexin/lipocortin inhibition, membrane lipid composition, cyclic dinucleotides, and developmental timing.
Why is phospholipase binding important in disease?
It controls arachidonic acid and eicosanoid production, lipid second messengers, bacterial immunity, and egg activation, linking it to inflammation, cardiovascular disease, cancer, and infertility.
What is the difference between phospholipase A2 and phospholipase C binding?
Distinct GTP-binding proteins bind and activate phospholipase A2 versus phospholipase C after alpha 1-adrenergic stimulation, showing pathway-specific coupling.
Which sperm factor binds phospholipase to activate the egg?
PLCZ1 and PAWP are the leading candidates, and the debate over which is the physiological sperm factor remains unresolved.
How do bacteria use phospholipase binding in CBASS immunity?
Cyclic dinucleotides induce filamentous assembly of phospholipase effectors, and CapV disrupts membranes through defined molecular mechanisms.
What methods study phospholipase binding?
Co-immunoprecipitation, lipid vesicle binding assays, structural biology, live-cell imaging, calcium imaging, and CRISPR perturbation are commonly used.
Can CRISPR knockout test phospholipase binding?
Yes, knockout of a candidate binder removes the interaction and reveals whether phospholipase-dependent signaling is lost.
What cell models are best for phospholipase binding research?
Knockout, point-mutation knock-in, tagged knock-in, and inducible overexpression models each answer different causal questions about phospholipase binding.
Conclusion
GO:0043274 phospholipase binding captures a central regulatory function in lipid signaling: the selective interaction of proteins with phospholipase enzymes. Verified literature shows that this binding controls receptor-coupled activation of phospholipase A2 and phospholipase C, inhibitory control by annexins/lipocortins, sperm-factor-driven egg activation, and bacterial CBASS immunity through phospholipase assembly. Because phospholipase binding sits upstream of second-messenger production and membrane remodeling, it is mechanistically and therapeutically important across inflammation, cardiovascular disease, cancer, and infertility. Studying phospholipase binding requires precise genetic models that separate binding from catalysis and expression. CRISPR knockout, point-mutation knock-in, tagged knock-in, overexpression, and library screening provide the causal toolkit, and EDITGENE offers these services to accelerate discovery in this field.
References
- 1. Nakai M et al.. 2020. Phospholipase Cζ (PLCζ) versus postacrosomal sheath WW domain-binding protein (PAWP): Which molecule will survive as a sperm factor?. Anim Sci J 91(1):e13345 PMID: 32219949
- 2. Wang J et al.. 2025. Cyclic-dinucleotide-induced filamentous assembly of phospholipases governs broad CBASS immunity.. Cell 188(14):3744-3756.e16 PMID: 40345202
- 3. Axelrod J et al.. 1988. Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers.. Trends Neurosci 11(3):117-23 PMID: 2465609
- 4. Kong J et al.. 2025. Molecular mechanisms of CBASS phospholipase effector CapV mediated membrane disruption.. Nat Commun 16(1):8611 PMID: 41022836
- 5. Goins CM et al.. 2018. Structural basis for lipid binding and mechanism of the Mycobacterium tuberculosis Rv3802 phospholipase.. J Biol Chem 293(4):1363-1372 PMID: 29247008
- 6. Burch RM et al.. 1986. Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells.. Proc Natl Acad Sci U S A 83(19):7201-5 PMID: 3020540
- 7. Tokuda M et al.. 1988. [Lipocortin--a Ca2+-binding protein which has anti-phospholipase A2 activity].. Seikagaku 60(1):26-31 PMID: 2969024
- 8. Jain MK et al.. 1988. Kinetics of binding of phospholipase A2 to lipid/water interfaces and its relationship to interfacial activation.. Biochim Biophys Acta 940(1):51-62 PMID: 3365431
